Ketoconazole

Edina Avdic, Pharm.D.
Pediatric Dosing Author: Bethany Chalk, Pharm.D., BCPPS
Ketoconazole is a topic covered in the Johns Hopkins ABX Guide.

To view the entire topic, please log in or purchase a subscription.

Official website of the Johns Hopkins Antibiotic (ABX), HIV, Diabetes, and Psychiatry Guides, powered by Unbound Medicine. Johns Hopkins Guide App for iOS, iPhone, iPad, and Android included. Explore these free sample topics:

Johns Hopkins Guides

MonkeypoxMonkeypox

Coronavirus COVID-19 (SARS-CoV-2)Coronavirus COVID-19 (SARS-CoV-2)

Suicide Risk in the COVID-19 PandemicSuicide Risk in the COVID-19 Pandemic

Moderna COVID-19 VaccineModerna COVID-19 Vaccine

BNT162b2 COVID-19 Vaccine (BioNTech/Pfizer)BNT162b2 COVID-19 Vaccine (BioNTech/Pfizer)

Managing Stress and Coping with COVID-19Managing Stress and Coping with COVID-19

Johnson & Johnson COVID-19 VaccineJohnson & Johnson COVID-19 Vaccine

-- The first section of this topic is shown below --

INDICATIONS

FDA

  • Systemic
    • Treatment of blastomycosis, coccidioidomycosis, histoplasmosis, chromomycosis, and paracoccidioidomycosis.
      • Note: despite FDA approval, due to the potential for severe hepatitis, adrenal insufficiency, and drug-drug interactions, systemic ketoconazole should not be used as a first-line treatment for any fungal infections.
  • Ketoconazole cream 2%
    • Treatment of tinea corporis, tinea cruris and tinea pedis caused by Trichophyton rubrum, T. mentagrophytes and Epidermophyton floccosum
    • Treatment of tinea (pityriasis) versicolor caused by Malassezia furfur (Pityrosporum orbiculare)
    • Treatment of cutaneous candidiasis caused by Candida spp.
    • Treatment of seborrheic dermatitis.
  • Ketoconazole shampoo 2%
    • Treatment of tinea (pityriasis) versicolor caused by or presumed to be caused by Pityrosporum orbiculare (also known as Malassezia furfur or M. orbiculare).

NON-FDA APPROVED USES

  • Treatment of hyperadrenalism
  • Booster for calcineurin inhibitor to increase levels in solid organ transplant recipients

-- To view the remaining sections of this topic, please log in or purchase a subscription --

INDICATIONS

FDA

  • Systemic
    • Treatment of blastomycosis, coccidioidomycosis, histoplasmosis, chromomycosis, and paracoccidioidomycosis.
      • Note: despite FDA approval, due to the potential for severe hepatitis, adrenal insufficiency, and drug-drug interactions, systemic ketoconazole should not be used as a first-line treatment for any fungal infections.
  • Ketoconazole cream 2%
    • Treatment of tinea corporis, tinea cruris and tinea pedis caused by Trichophyton rubrum, T. mentagrophytes and Epidermophyton floccosum
    • Treatment of tinea (pityriasis) versicolor caused by Malassezia furfur (Pityrosporum orbiculare)
    • Treatment of cutaneous candidiasis caused by Candida spp.
    • Treatment of seborrheic dermatitis.
  • Ketoconazole shampoo 2%
    • Treatment of tinea (pityriasis) versicolor caused by or presumed to be caused by Pityrosporum orbiculare (also known as Malassezia furfur or M. orbiculare).

NON-FDA APPROVED USES

  • Treatment of hyperadrenalism
  • Booster for calcineurin inhibitor to increase levels in solid organ transplant recipients

There's more to see -- the rest of this topic is available only to subscribers.

© 2000–2022 Unbound Medicine, Inc. All rights reserved